REVIEW article
Front. Immunol.
Sec. Microbial Immunology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1639606
This article is part of the Research TopicAdvances in Immunity and Microbiome: Exploring Key Interactions and InnovationsView all 8 articles
Immunomodulatory Roles of Butyrate in Asthma: Mechanisms and Therapeutic Potentials
Provisionally accepted- 1Chengdu University of Traditional Chinese Medicine, Chengdu, China
- 2Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Asthma, a chronic airway inflammatory disease driven by complex immune dysregulation, still remains a global health challenge despite its advances in biologic therapies. Butyrate, a major short-chain fatty acids (SCFAs) produced by intestinal microorganisms in the fermentation of dietary fiber, has recently garnered considerable attention for its multifaceted roles in maintaining immune homeostasis and modulating airway inflammation. This review summarizes the molecular mechanisms and recent advances by which butyrate alleviates asthmatic inflammation, including suppression of excessive activation of type 2 innate lymphoid cells (ILC2s) and T helper 2 (Th2) cells, inhibition of mast cells (MCs) degranulation, epigenetic modulation, regulation of receptor-mediated signaling pathways, and interactions along the gutlung axis. We integrate current knowledge of butyrate ' s multidimensional immunoregulatory network in asthma and propose a dual approach via microbiota-based interventions and targeted modulation of the immune microenvironmentto potentially overcome the limitations of conventional corticosteroid therapies. Despite its promising prospects, its clinical translation still faces many challenges, especially in airway specific delivery, improved bioavailability, and long-term safety. Innovative strategies, including nano-carrier engineering and targeted probiotic preparations are expected to improve their bioavailability and tissue specificity. Future research should focus on clarifying the dose-response relationship, long-term safety, and establishing individualized treatment stratification based on patients' microbiota-metabolic characteristics.
Keywords: Butyrate, Type 2 innate lymphoid cells, Histone deacetylase, Short Chain Fatty Acids, Immunity
Received: 02 Jun 2025; Accepted: 23 Jul 2025.
Copyright: © 2025 刘, Zeng, Chen, Fan, Huang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
超 刘, Chengdu University of Traditional Chinese Medicine, Chengdu, China
Qingsong Huang, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
Jianying Wu, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.